Abstract

Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a “pill burden” (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalData in Brief
Volume16
DOIs
Publication statusPublished - 01-02-2018

Fingerprint

etravirine
Pharmaceutical Preparations
Solubility
Reverse Transcriptase Inhibitors
Fourier Transform Infrared Spectroscopy
Area Under Curve
Permeability
High Pressure Liquid Chromatography
tartaric acid
HIV

All Science Journal Classification (ASJC) codes

  • General

Cite this

@article{568d45dacea34c7996a4643a6a453e77,
title = "Experimental data of co-crystals of Etravirine and L-tartaric acid",
abstract = "Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a “pill burden” (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.",
author = "Mikal Rekdal and Aravind pai and Muddukrishna BS",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.dib.2017.11.019",
language = "English",
volume = "16",
pages = "135--140",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

Experimental data of co-crystals of Etravirine and L-tartaric acid. / Rekdal, Mikal; pai, Aravind; BS, Muddukrishna.

In: Data in Brief, Vol. 16, 01.02.2018, p. 135-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimental data of co-crystals of Etravirine and L-tartaric acid

AU - Rekdal, Mikal

AU - pai, Aravind

AU - BS, Muddukrishna

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a “pill burden” (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.

AB - Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a “pill burden” (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.

UR - http://www.scopus.com/inward/record.url?scp=85034667850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034667850&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2017.11.019

DO - 10.1016/j.dib.2017.11.019

M3 - Article

VL - 16

SP - 135

EP - 140

JO - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -